Spectrum Of Activity
Age <50y 15 mg/kg (max 1 g) IM/IV q24h
Age ≥50y 10 mg/kg (max 750 mg) IM/IV q24h
Usual dose 15 mg/kg IM/IV q24h (max 1 g)
No dose adjustment
CrCl 90CrCl 70CrCl 50CrCl 30CrCl 20CrCl 10CrCl 0HD15 mg/kg IV q24h12 mg/kg IV q24h7.5 mg/kg IV q24h4 mg/kg IV q24h7.5 mg/kg IV q48h4 mg/kg IV q48h3 mg/kg IV q48h3 mg/kg IV q48h after HD
Black Box Warning: Patients treated with aminoglycosides by any route should be under close clinical observation because of the potential toxicity associated with their use. As with other aminoglycosides, the major toxic effects of kanamycin are its action on the auditory and vestibular branches of the eighth nerve and the renal tubules.
Measure peak (30-90 minutes after injection) and trough (just prior to the next dose) kanamycin serum concentrations intermittently during therapy.
Obtain acid-fast bacilli (AFB) smear and culture from sputum at least monthly until 2 consecutive culture specimens are negative.
Perform chest x-rays after 2 to 3 months of treatment in patients with negative initial cultures and at end of treatment.
Obtain serial audiograms and monitor vestibular function.
Monitor renal function; urine.
Neuromuscular paralysis, respiratory paralysis
Nondepolarizing neuromuscular blocking agents
Diuretic agents (e.g. Ethacrynic acid)
Cholera vaccine, live
Antimicrobial class: Aminoglycoside
Pregnancy category: D
Average serum half life: 2-3 hours
Biliary penetration: Moderate
CSF penetration: Poor